Pirfenidone - AMR-69

Based on 967 publications in PubMed 8 10 967

Axon 2647

CAS [53179-13-8]

MF C12H11NO
MW 185.22

  • Purity: 100%
  • Soluble in DMSO

Pirfenidone

Description

Orally available agent with therapeutic potential for idiopathic pulmonary fibrosis (IPF; IC50 value 14.44 mM for inhibition of cell proliferation against MRC-5 cells) that has combined anti-inflammatory, antioxidant and antifibrotic effects in experimental models of pulmonary fibrosis. Mechanistically, Pirfenidone inhibits not only TGF-β-induced Smad3, p38 and Akt phosphorylation in human lung fibroblasts (HLFs), but also significantly increased RGS2 mRNA and protein expression in fibroblasts.

KEYWORDS: Pirfenidone | supplier | anti-inflammatory | anti-fibrosis agent | AMR-69 | AMR69 | CAS [53179-13-8] | Immunology | idiopathic | pulmonary fibrosis | IPF | antioxidant | antifibrotic | TGF-β | Smad3 | p38 | Akt | RGS2

Order
Size Unit Price Stock
10 mg €60.00 In Stock
50 mg €120.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...